EGFR and breast cancer: Gefitinib [52] is another EGFR-tyrosine kinase inhibitor [53] implicated against liver and lung cancers [52] and it has exhibited its efficacy in mitigating the breast cancer cell proliferation of MCF-7 and BT-474 [54, 55].